A Phase 2 interventional study of SEL and FIR in Nonalcoholic Steatohepatitis (NASH) and Nonalcoholic Fatty Liver Disease (NAFLD), sponsored by Gilead Sciences. Completed at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-16.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Gilead Sciences.
Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, this one is the 7th largest by enrollment, is one of 6 that started in 2016, is one of 11 in phase 2, and was the 6th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →None of the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 6 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 220 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 161 across the 16 interventional studies. Of the 16 that completed or were terminated, 15 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the safety and tolerability of selonsertib, firsocostat, cilofexor, fenofibrate and/or Vascepa® in adults with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
Key Inclusion Criteria:
For Cohorts 1 through 6 and 9, individuals must meet the following conditions:
For Cohorts 7 and 8, individuals must have a clinical diagnosis of NAFLD and have at least one of the following criteria:
For Cohorts 10 and 11, individuals must have a clinical diagnosis of NAFLD and meet at least two criteria for metabolic syndrome modified from the NCEP ATP III Guidelines and one of the following criteria at Screening:
For Cohorts 12 and 13, individuals must have a clinical diagnosis of NAFLD/NASH and at least two criteria for metabolic syndrome as modified from the NCEPT ATP III Guidelines, OR one of the following criteria:
Key Exclusion Criteria:
History of a within 5 years of Screening with the following exceptions:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Non-cirrhotic participants will receive selonsertib (SEL) 18 mg tablet orally once daily for 12 weeks.
Drug: SEL
Non-cirrhotic participants will receive firsocostat (FIR) 20 mg tablet orally once daily for 12 weeks.
Drug: FIR
Non-cirrhotic participants will receive cilofexor (CILO) 30 mg tablet once daily for 12 weeks.
Drug: CILO
Non-cirrhotic participants will receive SEL 18 mg tablet + CILO 30 mg tablet once daily for 12 weeks.
Drug: SEL · Drug: CILO
Non-cirrhotic participants will receive SEL 18 mg tablet + FIR 20 mg tablet once daily for 12 weeks.
Drug: SEL · Drug: FIR
Non-cirrhotic participants will receive CILO 30 mg tablet + FIR 20 mg tablet once daily for 12 weeks.
Drug: FIR · Drug: CILO
Participants with Child-Pugh-Turcotte Class A cirrhosis will receive FIR 20 mg tablet once daily for 12 weeks.
Drug: FIR
Participants with Child-Pugh-Turcotte Class A cirrhosis will receive CILO 30 mg tablet once daily for 12 weeks.
Drug: CILO
Non-cirrhotic participants will receive SEL 18 mg tablet + FIR 20 mg tablet + CILO 30 mg tablet once daily for 12 weeks.
Drug: SEL · Drug: FIR · Drug: CILO
Participants will receive fenofibrate (FENO) 48 mg tablet orally once daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet + FENO 48 mg tablet orally once daily for 24 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
Drug: FIR · Drug: FENO
Participants will receive FENO 145 mg tablet orally once daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet + FENO 145 mg tablet orally once daily for 24 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
Drug: FIR · Drug: FENO
Participants will receive Vascepa® (VAS) 2 g capsule orally twice daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet once daily + CILO 30 mg tablet once daily + VAS 2 g capsule twice daily for 6 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
Drug: FIR · Drug: CILO · Drug: VAS
Participants will receive FENO 145 mg tablet orally once daily for 2 weeks in the pretreatment phase, then FIR 20 mg tablet once daily + CILO 30 mg tablet once daily + FENO 145 mg tablet orally once daily for 6 weeks in the treatment phase. Participants with compensated cirrhosis due to NASH will be accepted to participate in this cohort.
Drug: FIR · Drug: CILO · Drug: FENO
Percentage of Participants Who Experienced Treatment-Emergent Adverse Events
Treatment-emergent AEs were defined as events that met 1 or both of the following criteria: * Any AEs with onset dates on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug * Any AEs leading to premature discontinuation of study drug
Time frame: Cohorts 1-9: First dose date up to 12 weeks plus 30 days; Cohorts 10-11: First dose date up to 26 weeks plus 30 days; Cohorts 12-13: First dose date up to 8 weeks plus 30 days. For Cohorts 10-13, the first dose date included the Pre-treatment Phase.
Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events
A treatment emergent serious adverse event (SAE) was defined as an event that, at any dose, results in the following: * Death * Life-threatening * In-patient hospitalization or prolongation of existing hospitalization * Persistent or significant disability/incapacity * A congenital anomaly/birth defect * A medically important event or reaction
Time frame: Cohorts 1-9: First dose date up to 12 weeks plus 30 days; Cohorts 10-11: First dose date up to 26 weeks plus 30 days; Cohorts 12-13: First dose date up to 8 weeks plus 30 days. For Cohorts 10-13, the first dose date included the Pre-treatment Phase.
Percentage of Participants Who Experienced Grade 3 or Higher Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days for subjects who permanently discontinued study drug. If baseline laboratory data were missing, then any abnormality of at least Grade 1 was considered treatment emergent. Graded laboratory abnormalities were defined using the grading scheme in the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 for Cohorts 1-9 and CTCAE Version 5.0 for Cohorts 10-13.
Time frame: Cohorts 1-9: First dose date up to 12 weeks plus 30 days; Cohorts 10-11: First dose date up to 26 weeks plus 30 days; Cohorts 12-13: First dose date up to 8 weeks plus 30 days. For Cohorts 10-13, the first dose date included the Pre-treatment Phase.
Participants were enrolled in study sites in the United States and New Zealand. The first participant was screened on 13 June 2016. The last study visit occurred on 17 December 2020.
| Milestone | Cohort 1: SEL 18 mg (Non-cirrhotic) | Cohort 2: FIR 20 mg (Non-cirrhotic) | Cohort 3: CILO 30 mg (Non-cirrhotic) | Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic) | Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic) | Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic) | Cohort 7: CILO 20 mg (Cirrhotic) | Cohort 8: CILO 30 mg (Cirrhotic) | Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic) | Cohort 10: FIR 20 mg + FENO 48 mg | Cohort 11: FIR 20 mg + FENO 145 mg | Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g | Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 16 | 33 | 33 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 16 | 30 | 32 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 |
| Withdrew: Investigator's discretion | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Milestone | Cohort 1: SEL 18 mg (Non-cirrhotic) | Cohort 2: FIR 20 mg (Non-cirrhotic) | Cohort 3: CILO 30 mg (Non-cirrhotic) | Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic) | Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic) | Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic) | Cohort 7: CILO 20 mg (Cirrhotic) | Cohort 8: CILO 30 mg (Cirrhotic) | Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic) | Cohort 10: FIR 20 mg + FENO 48 mg | Cohort 11: FIR 20 mg + FENO 145 mg | Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g | Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 10 | 10 | 10 | 20 | 20 | 20 | 10 | 10 | 13 | 15 | 16 | 30 | 32 |
| Completed | 10 | 10 | 10 | 20 | 20 | 19 | 10 | 9 | 13 | 15 | 15 | 28 | 32 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 | 2 | 0 |
| Withdrew: Withdrew consent | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Treatment-emergent AEs were defined as events that met 1 or both of the following criteria: * Any AEs with onset dates on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug * Any AEs leading to premature discontinuation of study drug
| percentage of participants | Cohort 1: SEL 18 mg (Non-cirrhotic) | Cohort 2: FIR 20 mg (Non-cirrhotic) | Cohort 3: CILO 30 mg (Non-cirrhotic) | Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic) | Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic) | Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic) | Cohort 7: CILO 20 mg (Cirrhotic) | Cohort 8: CILO 30 mg (Cirrhotic) | Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic) | Cohort 10: FIR 20 mg + FENO 48 mg | Cohort 11: FIR 20 mg + FENO 145 mg | Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g | Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Experienced Treatment-Emergent Adverse Events | 50 | 60 | 50 | 25 | 40 | 50 | 80 | 70 | 76.92 | 86.67 | 87.5 | 40 | 37.5 |
A treatment emergent serious adverse event (SAE) was defined as an event that, at any dose, results in the following: * Death * Life-threatening * In-patient hospitalization or prolongation of existing hospitalization * Persistent or significant disability/incapacity * A congenital anomaly/birth defect * A medically important event or reaction
| percentage of participants | Cohort 1: SEL 18 mg (Non-cirrhotic) | Cohort 2: FIR 20 mg (Non-cirrhotic) | Cohort 3: CILO 30 mg (Non-cirrhotic) | Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic) | Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic) | Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic) | Cohort 7: CILO 20 mg (Cirrhotic) | Cohort 8: CILO 30 mg (Cirrhotic) | Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic) | Cohort 10: FIR 20 mg + FENO 48 mg | Cohort 11: FIR 20 mg + FENO 145 mg | Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g | Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events | 0 | 0 | 0 | 5 | 5 | 5 | 10 | 0 | 7.69 | 0 | 0 | 3.33 | 3.12 |
Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of last dose of study drug plus 30 days for subjects who permanently discontinued study drug. If baseline laboratory data were missing, then any abnormality of at least Grade 1 was considered treatment emergent. Graded laboratory abnormalities were defined using the grading scheme in the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 for Cohorts 1-9 and CTCAE Version 5.0 for Cohorts 10-13.
| percentage of participants | Cohort 1: SEL 18 mg (Non-cirrhotic) | Cohort 2: FIR 20 mg (Non-cirrhotic) | Cohort 3: CILO 30 mg (Non-cirrhotic) | Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic) | Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic) | Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic) | Cohort 7: CILO 20 mg (Cirrhotic) | Cohort 8: CILO 30 mg (Cirrhotic) | Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic) | Cohort 10: FIR 20 mg + FENO 48 mg | Cohort 11: FIR 20 mg + FENO 145 mg | Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g | Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Who Experienced Grade 3 or Higher Laboratory Abnormalities | 20 | 20 | 40 | 10 | 20 | 10 | 40 | 30 | 15.4 | 6.7 | 12.5 | 6.7 | 6.3 |
Collected over Adverse Events: First dose date up to last dose (Cohorts 1-9: up to 12 weeks; Cohorts 10-11: up to 26 weeks; Cohorts 12-13: up to 8 weeks) plus 30 days. For Cohorts 10-13, the first dose date included the Pre-treatment Phase. All-cause Mortality: Cohorts 1 through 6 and 9: Enrollment up to 12 weeks plus 30 days; Cohorts 7-8: Randomization up to 12 weeks plus 30 days; Cohorts 10-11: Randomization up to 26 weeks plus 30 days; Cohort 12-13: Randomization up to 8 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: SEL 18 mg (Non-cirrhotic) | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Cohort 2: FIR 20 mg (Non-cirrhotic) | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| Cohort 3: CILO 30 mg (Non-cirrhotic) | 0/10 (0%) | 0/10 (0%) | 5/10 (50%) |
| Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic) | 0/20 (0%) | 1/20 (5%) | 5/20 (25%) |
| Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic) | 0/20 (0%) | 1/20 (5%) | 8/20 (40%) |
| Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic) | 0/20 (0%) | 1/20 (5%) | 10/20 (50%) |
| Cohort 7: CILO 20 mg (Cirrhotic) | 0/10 (0%) | 1/10 (10%) | 8/10 (80%) |
| Cohort 8: CILO 30 mg (Cirrhotic) | 0/10 (0%) | 0/10 (0%) | 7/10 (70%) |
| Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic) | 0/13 (0%) | 1/13 (7.7%) | 10/13 (76.9%) |
| Cohort 10: FIR 20 mg + FENO 48 mg | 0/15 (0%) | 0/15 (0%) | 13/15 (86.7%) |
| Cohort 11: FIR 20 mg + FENO 145 mg | 0/16 (0%) | 0/16 (0%) | 14/16 (87.5%) |
| Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g | 0/30 (0%) | 1/30 (3.3%) | 7/30 (23.3%) |
| Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg | 0/32 (0%) | 1/32 (3.1%) | 9/32 (28.1%) |
| Event | Cohort 1: SEL 18 mg (Non-cirrhotic) | Cohort 2: FIR 20 mg (Non-cirrhotic) | Cohort 3: CILO 30 mg (Non-cirrhotic) | Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic) | Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic) | Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic) | Cohort 7: CILO 20 mg (Cirrhotic) | Cohort 8: CILO 30 mg (Cirrhotic) | Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic) | Cohort 10: FIR 20 mg + FENO 48 mg | Cohort 11: FIR 20 mg + FENO 145 mg | Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g | Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Small intestinal obstructionGastrointestinal disorders | 0/10 | 0/10 | 0/10 | 0/20 | 0/20 | 0/20 | 1/10 | 0/10 | 0/13 | 0/15 | 0/16 | 0/30 | 0/32 |
| Pneumonia viralInfections and infestations | 0/10 | 0/10 | 0/10 | 0/20 | 0/20 | 0/20 | 0/10 | 0/10 | 1/13 | 0/15 | 0/16 | 0/30 | 0/32 |
| CellulitisInfections and infestations | 0/10 | 0/10 | 0/10 | 1/20 | 0/20 | 0/20 | 0/10 | 0/10 | 0/13 | 0/15 | 0/16 | 0/30 | 0/32 |
| Tooth abscessInfections and infestations | 0/10 | 0/10 | 0/10 | 0/20 | 1/20 | 0/20 | 0/10 | 0/10 | 0/13 | 0/15 | 0/16 | 0/30 | 0/32 |
| Urinary tract infectionInfections and infestations | 0/10 | 0/10 | 0/10 | 0/20 | 0/20 | 1/20 | 0/10 | 0/10 | 0/13 | 0/15 | 0/16 | 0/30 | 0/32 |
| Non-cardiac chest painGeneral disorders | 0/10 | 0/10 | 0/10 | 0/20 | 0/20 | 0/20 | 0/10 | 0/10 | 0/13 | 0/15 | 0/16 | 1/30 | 0/32 |
| AppendicitisInfections and infestations | 0/10 | 0/10 | 0/10 | 0/20 | 0/20 | 0/20 | 0/10 | 0/10 | 0/13 | 0/15 | 0/16 | 0/30 | 1/32 |
| Event | Cohort 1: SEL 18 mg (Non-cirrhotic) | Cohort 2: FIR 20 mg (Non-cirrhotic) | Cohort 3: CILO 30 mg (Non-cirrhotic) | Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic) | Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic) | Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic) | Cohort 7: CILO 20 mg (Cirrhotic) | Cohort 8: CILO 30 mg (Cirrhotic) | Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic) | Cohort 10: FIR 20 mg + FENO 48 mg | Cohort 11: FIR 20 mg + FENO 145 mg | Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g | Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 1/10 | 0/10 | 0/10 | 0/20 | 1/20 | 2/20 | 0/10 | 1/10 | 5/13 | 1/15 | 4/16 | 1/30 | 1/32 |
| Upper respiratory tract infectionInfections and infestations | 0/10 | 0/10 | 1/10 | 0/20 | 0/20 | 2/20 | 0/10 | 0/10 | 2/13 | 5/15 | 1/16 | 0/30 | 0/32 |
| ConstipationGastrointestinal disorders | 1/10 | 0/10 | 0/10 | 0/20 | 1/20 | 0/20 | 0/10 | 0/10 | 3/13 | 3/15 | 1/16 | 0/30 | 1/32 |
| Back painMusculoskeletal and connective tissue disorders | 0/10 | 0/10 | 0/10 | 0/20 | 0/20 | 0/20 | 0/10 | 0/10 | 3/13 | 2/15 | 1/16 | 0/30 | 2/32 |
| AnaemiaBlood and lymphatic system disorders | 0/10 | 0/10 | 0/10 | 0/20 | 0/20 | 0/20 | 2/10 | 0/10 | 0/13 | 0/15 | 0/16 | 0/30 | 1/32 |
| Acute sinusitisInfections and infestations | 0/10 | 0/10 | 2/10 | 1/20 | 0/20 | 0/20 | 0/10 | 0/10 | 0/13 | 0/15 | 0/16 | 0/30 | 1/32 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/10 | 1/10 | 0/10 | 0/20 | 0/20 | 0/20 | 0/10 | 1/10 | 0/13 | 3/15 | 2/16 | 0/30 | 3/32 |
| DizzinessNervous system disorders | 0/10 | 0/10 | 0/10 | 0/20 | 0/20 | 1/20 | 1/10 | 2/10 | 2/13 | 1/15 | 2/16 | 0/30 | 0/32 |
| PruritusSkin and subcutaneous tissue disorders | 0/10 | 0/10 | 1/10 | 0/20 | 0/20 | 0/20 | 0/10 | 2/10 | 0/13 | 1/15 | 0/16 | 0/30 | 0/32 |
| Pruritus generalisedSkin and subcutaneous tissue disorders | 0/10 | 0/10 | 0/10 | 0/20 | 0/20 | 0/20 | 0/10 | 2/10 | 0/13 | 0/15 | 0/16 | 0/30 | 0/32 |
| Age, Continuous(years) | Cohort 1: SEL 18 mg (Non-cirrhotic) | Cohort 2: FIR 20 mg (Non-cirrhotic) | Cohort 3: CILO 30 mg (Non-cirrhotic) | Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic) | Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic) | Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic) | Cohort 7: CILO 20 mg (Cirrhotic) | Cohort 8: CILO 30 mg (Cirrhotic) | Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic) | Cohort 10: FIR 20 mg + FENO 48 mg | Cohort 11: FIR 20 mg + FENO 145 mg | Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g | Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 54 ± 7.0 | 57 ± 9.8 | 53 ± 12.3 | 56 ± 7.8 | 48 ± 13.8 | 55 ± 10.7 | 60 ± 11.1 | 60 ± 9.5 | 56 ± 8.2 | 59 ± 9.7 | 52 ± 14.2 | 56 ± 11.1 | 52 ± 11.5 | 55 ± 11.1 |
| Sex: Female, Male(Participants) | Cohort 1: SEL 18 mg (Non-cirrhotic) | Cohort 2: FIR 20 mg (Non-cirrhotic) | Cohort 3: CILO 30 mg (Non-cirrhotic) | Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic) | Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic) | Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic) | Cohort 7: CILO 20 mg (Cirrhotic) | Cohort 8: CILO 30 mg (Cirrhotic) | Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic) | Cohort 10: FIR 20 mg + FENO 48 mg | Cohort 11: FIR 20 mg + FENO 145 mg | Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g | Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 9 | 5 | 9 | 13 | 11 | 12 | 7 | 6 | 11 | 10 | 9 | 24 | 22 | 148 |
| Male | 1 | 5 | 1 | 7 | 9 | 8 | 3 | 4 | 2 | 5 | 7 | 6 | 10 | 68 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: SEL 18 mg (Non-cirrhotic) | Cohort 2: FIR 20 mg (Non-cirrhotic) | Cohort 3: CILO 30 mg (Non-cirrhotic) | Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic) | Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic) | Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic) | Cohort 7: CILO 20 mg (Cirrhotic) | Cohort 8: CILO 30 mg (Cirrhotic) | Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic) | Cohort 10: FIR 20 mg + FENO 48 mg | Cohort 11: FIR 20 mg + FENO 145 mg | Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g | Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 8 | 9 | 8 | 12 | 5 | 11 | 6 | 3 | 9 | 2 | 10 | 15 | 17 | 115 |
| Not Hispanic or Latino | 2 | 1 | 2 | 8 | 15 | 9 | 4 | 7 | 4 | 13 | 6 | 15 | 15 | 101 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: SEL 18 mg (Non-cirrhotic) | Cohort 2: FIR 20 mg (Non-cirrhotic) | Cohort 3: CILO 30 mg (Non-cirrhotic) | Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic) | Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic) | Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic) | Cohort 7: CILO 20 mg (Cirrhotic) | Cohort 8: CILO 30 mg (Cirrhotic) | Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic) | Cohort 10: FIR 20 mg + FENO 48 mg | Cohort 11: FIR 20 mg + FENO 145 mg | Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g | Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asian | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 5 |
| Black or African American | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Native Hawaiian or Pacific Islander | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| White | 10 | 10 | 10 | 19 | 17 | 17 | 10 | 10 | 12 | 14 | 16 | 30 | 30 | 205 |
| Other | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Region of Enrollment(Participants) | Cohort 1: SEL 18 mg (Non-cirrhotic) | Cohort 2: FIR 20 mg (Non-cirrhotic) | Cohort 3: CILO 30 mg (Non-cirrhotic) | Cohort 4: SEL 18 mg + CILO 30 mg (Non-cirrhotic) | Cohort 5: SEL 18 mg + FIR 20 mg (Non-cirrhotic) | Cohort 6: CILO 30 mg + FIR 20 mg (Non-cirrhotic) | Cohort 7: CILO 20 mg (Cirrhotic) | Cohort 8: CILO 30 mg (Cirrhotic) | Cohort 9: SEL 18 mg + FIR 20 mg + CILO 30 mg (Non-cirrhotic) | Cohort 10: FIR 20 mg + FENO 48 mg | Cohort 11: FIR 20 mg + FENO 145 mg | Cohort 12: FIR 20 mg + CILO 30 mg + VAS 2g | Cohort 13: FIR 20 mg + CILO 30 mg + FENO 145 mg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| New Zealand | 0 | 0 | 0 | 0 | 3 | 3 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 7 |
| United States | 10 | 10 | 10 | 20 | 17 | 17 | 10 | 10 | 12 | 15 | 16 | 30 | 32 | 209 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2016 to primary completion in Dec 2020, 54 months.
Results were first posted in Feb 2022, 1 year 1 month after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 54 months is above that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Selonsertib · Firsocostat · Cilofexor
Non-alcoholic Fatty Liver Disease →